Last updated on September 2018

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)


Brief description of study

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy will be treated with pembrolizumab.

Clinical Study Identifier: NCT02628067

Contact Investigators or Research Sites near you

Start Over

Paul Duffy

Merck Sharp & Dohme Ltd.
Hoddesdon, United Kingdom
  Connect »